China Sickle Cell Disease Drug Market Analysis

China Sickle Cell Disease Drugs Market Analysis

$ 3999

This report presents a strategic analysis of the China Sickle Cell Disease Drugs Market Analysis and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the China Sickle Cell Disease Drugs Market Analysis, offering unmatched value, accuracy, and expert insights.

ID: IN10CNPH559 CATEGORY: Pharmaceuticals GEOGRAPHY: China

Buy Now

China Sickle Cell Disease Drugs Market Analysis Executive Summary

Sickle cell disease (SCD) is a genetic red blood cell (RBC) disorder that affects hemoglobin, a protein that carries oxygen throughout the body. Numerous consequences result from it, including acute chest syndrome, anemia, and vaso-occlusive crisis (VOC). Currently, doctors frequently recommend bone marrow and blood transplants to treat SCD. It entails removing the damaged bone marrow and replacing it with healthy bone marrow obtained from a donor. As they can lessen particular symptoms and extend patients' lives, other efficient treatments including pharmaceuticals and blood transfusions are also being used.

Market Size and Key Findings

The China Sickle Cell Disease Drugs Market Analysis size is around US $ xx Bn in 2021 and is projected to reach US $ xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period.

China Sickle Cell Disease Drugs Market Analysis Size (In $Bn)

(2021-2030F)

Market Dynamics

Market Growth Drivers Analysis

One of the important reasons driving the demand for new pharmaceuticals that can effectively treat the condition is the huge rise in the number of people with SCD. As a result, the health regulatory agencies of many nations are concentrating on expediting the licensing of new treatment modalities. For instance, in 2019 the US Food and Drug Administration (USFDA) approved a novel drug to lessen the pain that both adults and children with SCD feel. Additionally, government agencies are funding research and development (R&D) initiatives to motivate academics and pharmaceutical firms to create innovative therapies. For instance, scientists at the National Heart, Lung, and Blood Institute (NHLBI) in the US are developing genetic medicines that can replace a gene that has been lost or add a new DNA strain to enhance cellular function. It is projected that these advances would help fuel market expansion, combined with rising disposable incomes and increased consumer awareness of healthcare options.

Market Restraints

The high expense of treating sickle cell illness and its adverse effects, which include headache, nausea, diarrhea, exhaustion, rash, and fever, are anticipated to restrain the market for treatments for sickle cell disease.

Competitive Landscape

Key Players

Some of the key companies are Agios Pharmaceuticals, Bristol-Myers Squibb, CRISPR Therapeutics, editas Medicine, Emmaus Life Sciences, Inc., Global Blood Therapeutics, Inc., Medunic USA Inc., Novartis AG, Novo Nordisk, Vifor Pharma

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

China Sickle Cell Drug Market Segmentation

By Type (Revenue, USD Billion):

The market is divided based on type into HbSS, also known as sickle cell anemia, HbSC, and others (HbS beta thalassemia, HbSD, HbSE, and HbSO). Due to the rise in complications associated with sickle cell anemia, such as hemolysis and vaso-occlusive crisis, the sickle cell anemia segment generated the most revenue in 2021 and is anticipated to maintain its dominance during the forecast period for the sickle cell disease treatment market.

Sickle Cell Anemia
HbSC
Others

By Drug Type (Revenue, USD Billion):

The market is divided into hydroxyurea, oxbryta, adakveo, and other categories depending on the type of medicine. In 2021, the global market for treating sickle cell disease was dominated by the hydroxyurea segment. The rise of the category is fueled by hydroxyurea, which is an excellent treatment option for sickle cell anemia and offers therapeutic benefits through numerous mechanisms of action. However, it is anticipated that during the forecast period, the adakveo category will increase at the quickest rate. This is due to an increase in the use of the medicine Adakveo for the treatment of the vaso-occlusive crisis (VOC) caused by sickle cell illness, which will cause demand for Adakveo to increase throughout the forecast period.

Hydroxyurea
- 4.2.1.1 Distribution Channel
  - Hospitals Pharmacies
  - Drug Stores and Retail Pharmacies
  - Online Providers
Oxybryta
Adakveo
Others

By Route of Administration (Revenue, USD Billion):

The market is divided into oral and parenteral segments based on the route of administration. The oral segment generated the most revenue in 2021 as a result of the widespread use of oral medications due to their noninvasive nature, high patient compliance, portability, and lack of any special sterile requirements.

Oral
Parenteral

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.